8-K: Celularity Inc. Changes Auditors and Board Member Resigns

Celularity Inc. has dismissed Deloitte & Touche LLP as its independent auditor and engaged EisnerAmper LLP, while also seeing the resignation of a board member, Marc Mazur.

Summary

• Celularity Inc. dismissed Deloitte & Touche LLP as their independent registered public accounting firm on August 2, 2024.
• The dismissal was approved by the Audit Committee of the Board of Directors.
• Deloitte's reports on Celularity's financial statements for 2022 and 2023 did not contain any adverse opinions or disclaimers, but did include an explanatory paragraph about the company's ability to continue as a going concern.
• There were no disagreements between Celularity and Deloitte on accounting principles, financial disclosures, or auditing procedures.
• EisnerAmper LLP was engaged as the new independent registered public accounting firm on August 2, 2024.
• EisnerAmper will audit Celularity's consolidated financial statements for the year ending December 31, 2024.
• EisnerAmper will also review the unaudited interim financial statements for the quarters ended March 31, 2024 and June 30, 2024.
• Marc Mazur resigned from the Board of Directors and all committees on July 31, 2024.
• Mr. Mazur's resignation was not due to any disagreements with the company.

Sentiment

Score: 3

Explanation: The change of auditors combined with the going concern note from the previous auditor is a significant negative signal, indicating potential financial instability and uncertainty. The resignation of a board member adds to the negative sentiment.

Positives

• The transition to a new auditor, EisnerAmper, was completed quickly and without any reported issues.
• The resignation of Marc Mazur was not due to any disagreements with the company.

Negatives

• Deloitte's reports included an explanatory paragraph about Celularity's ability to continue as a going concern, indicating financial uncertainty.
• The company has changed auditors, which can sometimes be a sign of underlying issues.

Risks

• The going concern note in Deloitte's reports raises concerns about Celularity's financial stability.
• Changing auditors can sometimes lead to increased scrutiny and potential adjustments to financial statements.
• The resignation of a board member, even without stated disagreements, can create uncertainty.

Future Outlook

The company will be working with EisnerAmper to complete the audit for the year ending December 31, 2024, and review the interim financial statements for the quarters ended March 31, 2024 and June 30, 2024.

Management Comments

• Marc Mazur's decision to resign was not due to any disagreement with Celularity on any matter, or relating to its operations, policies, or practices.

Industry Context

Changes in auditors are not uncommon, but the going concern note and the change of auditors may raise concerns among investors in the biotech industry, where financial stability is critical.

Comparison to Industry Standards

• The change of auditors is not unusual, but the going concern qualification is a significant concern. Many biotech companies, especially those in the development stage, face financial challenges, but a going concern qualification is a red flag.
• Companies like Fate Therapeutics and CRISPR Therapeutics, while also in the biotech space, have not recently reported similar auditor changes or going concern issues, suggesting Celularity's situation may be more precarious.
• The resignation of a board member is also not uncommon, but the timing alongside the auditor change may raise questions about internal stability.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the company's financial stability due to the going concern note and auditor change.
• Employees may be concerned about the company's future prospects.
• Creditors may be more cautious about extending credit to the company.

Next Steps

• EisnerAmper will commence work on the audit for the year ending December 31, 2024.
• EisnerAmper will review the unaudited interim financial statements for the quarters ended March 31, 2024 and June 30, 2024.
• The company will need to address the going concern issue to reassure investors.

Key Dates

Keywords

auditor, Deloitte, EisnerAmper, accounting, board of directors, resignation, financial statements, going concern